Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated a new insulin delivery system designed to reduce insulin delivery when trends in continuous glucose monitoring (CGM) glucose concentrations predict future hypoglycemia. RESEARCH DESIGN AND METHODS: Individuals with type 1 diabetes (n = 103, age 6–72 years, mean HbA1c 7.3% [56 mmol/mol]) participated in a 6-week randomized crossover trial to evaluate the efficacy and safety of a Tandem Diabetes Care t:slim X2 pump with Basal-IQ integrated with a Dexcom G5 sensor and a predictive low-glucose suspend algorithm (PLGS) compared with sensor-augmented pump (SAP) therapy. The primary outcome was CGM-measured time <70 mg/dL. RESULTS: Both study periods were completed by 99% of participants; median CGM usage exceeded 90% in both arms. Median time <70 mg/dL was reduced from 3.6% at baseline to 2.6% during the 3-week period in the PLGS arm compared with 3.2% in the SAP arm (difference [PLGS − SAP] = −0.8%, 95% CI −1.1 to −0.5, P < 0.001). The corresponding mean values were 4.4%, 3.1%, and 4.5%, respectively, represent-ing a 31% reduction in the time <70 mg/dL with PLGS. There was no increase in mean glucose concentration (159 vs. 159 mg/dL, P = 0.40) or percentage of time spent >180 mg/dL (32% vs. 33%, P = 0.12). One severe hypoglycemic event occurred in the SAP arm and none in the PLGS arm. Mean pump suspension time was 104 min/day. CONCLUSIONS: The Tandem Diabetes Care Basal-IQ PLGS system significantly reduced hypoglycemia without rebound hyperglycemia, indicating that the system can benefit adults and youth with type 1 diabetes in improving glycemic control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Partial closed-loop therapy, such as predictive low-glucose suspend (PLGS) technology, has been shown in nonpregnant people to be better than sensoraugmented insulin pumps (SAP) for reducing low glucose values (108).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [108]
In the citing paper
“Both generation 1 low-glucose-suspend33 and generation 2 hybrid closed-loop systems improve glycated haemoglobin concentrations, the time in target range and the time below target range in children, adolescents34 and adults.35-37”
From Blood glucose monitoring devices: current considerations (2023) · cites this paper as [33]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [25]
In the citing paper
“Predictive lowglucose suspend systems have been shown to reduce time spent with glucose <70 mg/dL without rebound hyperglycemia during a 6-week randomized crossover trial (190).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [190]
Citations
Cites
Adaptive linear step-up procedures that control the false discovery rate
Benjamini, Y., Krieger, A. M., & Yekutieli, D. (2006) · Biometrika · doi:10.1093/biomet/93.3.491 · Cited by 3,228 · cited 1×
“All nominal (uncorrected) P values except those from the primary and safety analyses were adjusted for multiple comparisons using the Benjamini-Hochberg adaptive false discovery procedure (24).”
MethodInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“Percentage of time,54 mg/dL was added as a post hoc outcome to conform with a recent consensus classification of hypoglycemia (21).”
MethodSelf-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Estimates of Location Based on Rank Tests
Hodges, J. L., & Lehmann, E. L. (1963) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177704172 · Cited by 1,260 · cited 1×
“parametric analysis based on ranks was performed (23).”
MethodMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 5×
“ticipants using an insulin pump and CGM before the study were higher and baseline HbA1c levels were lower than the national averages for adults and children with type 1 diabetes (9).”
BackgroundInfluentialSelf-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“8% fewer nocturnal hypoglycemia events using a threshold suspend system compared with sensor-augmented pump (SAP) therapy (10).”
MethodSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Determining what individual SUS scores mean
(2009) · Journal of Usability Studies archive · doi:10.5555/2835587.2835589 · Cited by 412
Cited by
Items 201–247 of 247
Artificial Pancreas Blood Glucose-Insulin Regularization System Using PID Controller
Das, R. R., Bagadi, K., Sona, D. R., Balaji, D., Raja, N., & Samundeeswari, N. (2023) · Innovations in Power and Advanced Computing Technologies (i-PACT) · doi:10.1109/i-pact58649.2023.10434738 · Cited by 1
Mesa, A., Roca, D., Granados, M., Pueyo, I., Cabré, C., Amor, A. J., Solà, C., Matas, O., Castanys, J., Conget, I., et al. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.11.004 · Cited by 1
Artificial pancreas in pediatrics
Forlenza, G. P., Messer, L. H., Maahs, D. M., & Cherñavvsky, D. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00020-x · Cited by 1
Self-citationPädiatrie – Motor der technologischen Weiterentwicklung in der Diabetologie
Biester, T., & Kordonouri, O. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0484-6 · Cited by 3
Updates on Technology for Diabetes Mellitus
Elshimy, G., & Correa, R. (2020) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-020-00204-7 · Cited by 1
Predictive low glucose suspend systems
Forlenza, G. P., & Ekhlaspour, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00014-4 · Cited by 1
Self-citationBerge, T. V. D., Remus, K., Biester, S., Reschke, F., Datz, N., Danne, T., Kordonouri, O., & Biester, T. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1720-8882 · Cited by 1
Aktueller Stand der Insulinpumpentherapie in der Kinderdiabetologie
Berge, T. V. D., Reschke, F., & Biester, T. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1780-3779 · Cited by 1
The dawn of automated insulin delivery: from promise to product
Nally, L. M., & Sherr, J. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00016-8
WEINZIMER, S. A., CARRIA, L. R., & Name, M. A. V. (2021) · Contemporary Endocrinology · doi:10.1007/978-3-030-64133-7_8
Self-citationDiagnosis and Management of Pediatric Diseases
Sergi, C. M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-967-4
Erfolgreiche Nutzung von prädiktiver Insulinabschaltung: Vergleich zweier Systeme
Berge, T. V. D., Remus, K., Biester, S., Reschke, F., Datz, N., Kapitzke, K., Kordonouri, O., Danne, T., & Biester, T. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/s-0041-1730858
Therapeutic potential of zein-based nanoparticles
Reboredo, C. (2022) · doi:10.15581/10171/62894
Forde, H. E., Wilmot, E. G., & Choudhary, P. (2021) · Diabetic Medicine · doi:10.1111/dme.14546
Doyle, E. A., Cengiz, E., & Tamborlane, W. V. (2021) · Contemporary Endocrinology · doi:10.1007/978-3-030-64133-7_6
Self-citationCarty, D. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch10
Delgado, A. M., & Lucas, F. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.06.002 · Cited by 1
Reinhart-Steininger, B., Schütz-Fuhrmann, I., & Stulnig, T. M. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00184-x
Aktueller Stand der Insulinpumpentherapie in der Kinderdiabetologie
Berge, T. V. D., Reschke, F., & Biester, T. (2023) · Pädiatrie up2date · doi:10.1055/a-1981-4040
“Wird ein festgelegter Grenzwert in dieser Berechnung unterschritten, wird die Insulinzufuhr, je nach System, für eine Dauer von 5–120 min unterbrochen [7, 8].”
BackgroundJacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.15.23288624
“All of these trials demonstrated significant improvements in measures of hypoglycemia with either a PLGS or LGS system.(63,64,66,67,69,71) In one trial, change in HbA1c was the primary outcome, and the PLGS arm was found to be superior to the control group.”
BackgroundResultAslan, A., Díez, J.-L., Sanz, A. J. L., & Bondía, J. (2023) · Applied Sciences · doi:10.3390/app13095348
Using Diabetes Technology to Maximize Diabetes Management
Young, C. F., Wong, S. M., & Vanderwyk, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95884-4.00006-8
Stem Cell Therapy in Diabetes Mellitus
Saeed, A. G., & Sebaiy, M. M. (2023) · Journal of Clinical and Medical Reviews · doi:10.58489/2836-2330/013
Erste pädiatrische Nutzung eines AID-Systems mit automatischem Korrekturbolus in Deutschland
Berge, T. V. D., Biester, S., Remus, K., Reschke, F., Klusmeier, B., Adolph, K., Kordonouri, O., Danne, T., & Biester, T. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2131-5432
“Im Vergleich zu SUP ohne Automatisierung haben pädiatrische Studien den Nutzen einer schwellenwertba-sierten sowie einer prädiktiven Niedrigglukoseunterbrechung (PLGM) für die Reduktion von Hypoglykämien gezeigt [4, 5].”
BackgroundZozulińska‐Ziółkiewicz, D., Malecki, M. T., Czupryniak, L., Jarosz-Chobot, P. A., Klupa, T., Myśliwiec, M., Szadkowska, A., Szypowska, A., Gawrecki, A., Mianowska, B., et al. (2021) · Current Topics in Diabetes · doi:10.5114/ctd/146220
New Technologies for Insulin Administration
Forde, H. E., & Choudhary, P. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch33
Mesa, A., Roca, D., Granados, M., Pueyo, I., Cabré, C., Amor, A. J., Solà, C., Matas, O., Castanys, J., Conget, I., et al. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.05.012
Suganuma, Y., Ishiguro, M., Ohno, T., & Nishimura, R. (2024) · Diabetology International · doi:10.1007/s13340-024-00743-4
Other Considerations in Pump Therapy Management
(2024) · American Diabetes Association eBooks · doi:10.2337/9781580408363.ch07
Objetivos del tratamiento de la diabetes mellitus tipo 1
Cebada, A. B., da Silva, J. K. H., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.002 · Cited by 2
Tecnología aplicada a la diabetes
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.004
Cengiz, E. (2019) · doi:10.2337/9781580406932.part1_ch03
Self-citationInnovaciones tecnológicas y diabetes
Lablanche, S., Delagenière, J., & Jalbert, M. (2025) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(25)50386-0
Technological innovations in the treatment of diabetes over the last decade
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00011-1
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Insulin pumps and artificial pancreas
Markakis, K. P., & Vazeou, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00296-x
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
A Review on Hybrid Closed Loop Insulin Delivery System
Kuralarasan, S. G. (2025) · Advances in Applied Biological Research · doi:10.48165/aabr.2025.2.2.04
Nanoparticle-based insulin delivery: route-specific barriers, innovations, and therapeutic outcomes
Al‐Nemrawi, N. K., Nimrawi, S., Mustafa, E., Al-Adawi, M. E., Al-Thunaibat, R., Al-Adwan, S. R., & Kwon, Y. M. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2678326
Nanotechnology and drug delivery: Fundamentals and applications
Purohit, A., Nema, P., Kumar, A., Kumar, N. D., Soni, V., & Kashaw, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44119-6.00017-3
Advanced Technology in Diabetes: Sensors and Pumps
Forlenza, G. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00023-8
Self-citationYamaoka, T., Sugiyama, T., Kashiwagi, K., Furuno, T., Yamamoto, K., Imai, K., Ihana‐Sugiyama, N., Nishioka, Y., Ohsugi, M., Ueki, K., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113462
Digital Health Technologies and Hypoglycaemia
Villard, O., & Renard, É. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_24
Current options in insulin pump therapy for diabetes
Radovnická, L. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2026.020
Gopalan, B., Vijaya, G. S., & Ulle, R. S. (2026) · IGI Global eBooks · doi:10.4018/979-8-2600-4190-1.ch001
Metadata
- Authors
- Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., Marcal, T., Andre, C., Carria, L., Swanson, V., Lum, J. W., Kollman, C., Woodall, W., & Beck, R. W.
- Affiliations
- University of Colorado Denver (US)
- Jaeb Center for Health Research (US)
- Stanford Medicine (US)
- Sansum Diabetes Research Institute (US)
- Yale University (US)
- Tandem Diabetes Care (United States) (US)
- Corresponding author
- Lum, John W.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-08
- Volume
- 41
- Issue
- 10
- Pages
- 2155-2161
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2886691517
- Cited by
- 246
- References
- 32
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 30 · 2023: 32 · 2022: 28 · 2021: 50 · 2020: 38 · 2019: 41 · 2018: 2
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, hypoglycemia, predictive low glucose suspend, continuous glucose monitoring, insulin pump therapy, sensor-augmented pump, glycemic control, adolescents, children
- MeSH terms
- Adolescent, Adult, Aged, Algorithms, Blood Glucose, Child, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Blood Glucose Self-Monitoring, Drug Delivery Systems, Cross-Over Studies, Monitoring, Ambulatory, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.